Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprepitant

Drug Profile

Aprepitant

Alternative Names: Emend; L-754030; MK-0869; MK-869; ONO-7436

Latest Information Update: 12 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Fudan University Shanghai Cancer Center; Hunan Province Tumor Hospital; Merck & Co; Ono Pharmaceutical
  • Class Antidepressants; Antiemetics; Fluorobenzenes; Morpholines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 10 Apr 2018 Merck has patent protection for aprepitant in USA, Europe and Japan
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(In adolescents, In children, Prevention) in Brazil (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(In adolescents, In children, Prevention) in Mexico (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top